CTRI/2024/08/072027尚未招募Unknown
ICMRs Multistate Implementation Research Study on Suicide Risk Reduction and Improving Mental Well Being Among School and College Students - NI
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. School/ pre-university students (grades 9-12)
- •2. College students (graduate and postgraduate levels, including professional courses)
排除标准
- •1. Educational institutes exclusively catering to adolescents with special needs
- •2. Doctoral students and students pursuing education through distance or online or certificate courses lasting less than a year
研究者
相似试验
已完成
不适用
International survey to investigate the implementation of daily ICU care for patients with and without COVID-19 infection. A Point Prevalence Study -ISIIC 2 Studypatients in ICJPRN-UMIN000043864Saiseikai Utsunomiya Hospital Hitachi General Hospital1,229
招募中
不适用
Dementia-friendly book clubs in the care home: can quality of life be improved? A randomized clinical trialDementiaACTRN12618001269224niversity of Otago260
已完成
1 期
Pilot study "International collaborative investigation of underlying technology to develop information exchange platform with hairdresser and barber for successful aging in Thailand and Japan"Shop owner and customers in hairdresser/barberJPRN-UMIN000023733Akita University12
进行中（未招募）
不适用
A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage HER2-positive breast cancer.Treatment of HER2 positive adjuvant or neoadjuvant therapyMedDRA version: 12.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2010-019752-50-DEF. Hoffmann-La Roche Ltd135
进行中（未招募）
1 期
A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage HER2-positive breast cancer.Treatment of HER2 positive adjuvant or neoadjuvant therapyMedDRA version: 12.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2010-019752-50-BEF. Hoffmann-La Roche Ltd135